Search

Your search keyword '"Musto, Pellegrino"' showing total 16 results
Start Over Author "Musto, Pellegrino" Journal international journal of molecular sciences
16 results on '"Musto, Pellegrino"'

1. The Role of NLRP3, a Star of Excellence in Myeloproliferative Neoplasms

Author

Parciante, Elisa, primary, Cumbo, Cosimo, additional, Anelli, Luisa, additional, Zagaria, Antonella, additional, Redavid, Immacolata, additional, Minervini, Angela, additional, Conserva, Maria Rosa, additional, Tota, Giuseppina, additional, Coccaro, Nicoletta, additional, Tarantini, Francesco, additional, Minervini, Crescenzio Francesco, additional, Macchia, Maria Giovanna, additional, Specchia, Giorgina, additional, Musto, Pellegrino, additional, and Albano, Francesco, additional

Published
2023
Full Text
View/download PDF

2. IKAROS in Acute Leukemia: A Positive Influencer or a Mean Hater?

Author

Conserva, Maria Rosa, primary, Redavid, Immacolata, additional, Anelli, Luisa, additional, Zagaria, Antonella, additional, Tarantini, Francesco, additional, Cumbo, Cosimo, additional, Tota, Giuseppina, additional, Parciante, Elisa, additional, Coccaro, Nicoletta, additional, Minervini, Crescenzio Francesco, additional, Minervini, Angela, additional, Specchia, Giorgina, additional, Musto, Pellegrino, additional, and Albano, Francesco, additional

Published
2023
Full Text
View/download PDF

3. Molecular Features and Diagnostic Challenges in Alpha/Beta T-Cell Large Granular Lymphocyte Leukemia

Author

Gaudio, Francesco, primary, Masciopinto, Pierluigi, additional, Bellitti, Emilio, additional, Musto, Pellegrino, additional, Arcuti, Elena, additional, Battisti, Olga, additional, Cazzato, Gerardo, additional, Solombrino, Alessandra, additional, Laddaga, Filomena Emanuela, additional, Specchia, Giorgina, additional, Maiorano, Eugenio, additional, and Ingravallo, Giuseppe, additional

Published
2022
Full Text
View/download PDF

8. Epitranscriptomics in Normal and Malignant Hematopoiesis

Author

Minervini, Crescenzio Francesco, primary, Parciante, Elisa, additional, Impera, Luciana, additional, Anelli, Luisa, additional, Zagaria, Antonella, additional, Specchia, Giorgina, additional, Musto, Pellegrino, additional, and Albano, Francesco, additional

Published
2020
Full Text
View/download PDF

9. Future in the Past: Azorella glabra Wedd. as a Source of New Natural Compounds with Antiproliferative and Cytotoxic Activity on Multiple Myeloma Cells

Author

Lamorte, Daniela, primary, Faraone, Immacolata, additional, Laurenzana, Ilaria, additional, Milella, Luigi, additional, Trino, Stefania, additional, De Luca, Luciana, additional, Del Vecchio, Luigi, additional, Armentano, Maria, additional, Sinisgalli, Chiara, additional, Chiummiento, Lucia, additional, Russo, Daniela, additional, Bisaccia, Faustino, additional, Musto, Pellegrino, additional, and Caivano, Antonella, additional

Published
2018
Full Text
View/download PDF

13. Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study

Author

Almeida, Antonio, primary, Prebet, Thomas, additional, Itzykson, Raphael, additional, Ramos, Fernando, additional, Al-Ali, Haifa, additional, Shammo, Jamile, additional, Pinto, Ricardo, additional, Maurillo, Luca, additional, Wetzel, Jaime, additional, Musto, Pellegrino, additional, Van De Loosdrecht, Arjan, additional, Costa, Maria, additional, Esteves, Susana, additional, Burgstaller, Sonja, additional, Stauder, Reinhard, additional, Autzinger, Eva, additional, Lang, Alois, additional, Krippl, Peter, additional, Geissler, Dietmar, additional, Falantes, Jose, additional, Pedro, Carmen, additional, Bargay, Joan, additional, Deben, Guillermo, additional, Garrido, Ana, additional, Bonanad, Santiago, additional, Diez-Campelo, Maria, additional, Thepot, Sylvain, additional, Ades, Lionel, additional, Sperr, Wolfgang, additional, Valent, Peter, additional, Fenaux, Pierre, additional, Sekeres, Mikkael, additional, Greil, Richard, additional, and Pleyer, Lisa, additional

Published
2017
Full Text
View/download PDF

14. Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine

Author

Simeon, Vittorio, primary, Todoerti, Katia, additional, La Rocca, Francesco, additional, Caivano, Antonella, additional, Trino, Stefania, additional, Lionetti, Marta, additional, Agnelli, Luca, additional, De Luca, Luciana, additional, Laurenzana, Ilaria, additional, Neri, Antonino, additional, and Musto, Pellegrino, additional

Published
2015
Full Text
View/download PDF

15. Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine

Author

Vittorio Simeon, Antonella Caivano, Francesco La Rocca, Marta Lionetti, Katia Todoerti, Stefania Trino, Luca Agnelli, Luciana De Luca, Ilaria Laurenzana, Antonino Neri, Pellegrino Musto, Simeon, Vittorio, Todoerti, Katia, La Rocca, Francesco, Caivano, Antonella, Trino, Stefania, Lionetti, Marta, Agnelli, Luca, De Luca, Luciana, Laurenzana, Ilaria, Neri, Antonino, and Musto, Pellegrino

Subjects
Oncology, medicine.medical_specialty, medicine.medical_treatment, molecular profiling, precision medicine, MEDLINE, Antineoplastic Agents, Review, Disease, risk stratification, Catalysis, Leukemia, Plasma Cell, Targeted therapy, Inorganic Chemistry, lcsh:Chemistry, Internal medicine, plasma cell leukemia, medicine, Humans, Molecular Targeted Therapy, Physical and Theoretical Chemistry, Molecular Biology, lcsh:QH301-705.5, Spectroscopy, Multiple myeloma, pharmacogenetics, Plasma cell leukemia, business.industry, Organic Chemistry, General Medicine, Prognosis, Precision medicine, medicine.disease, Neoplasm Proteins, Computer Science Applications, Leukemia, Treatment Outcome, lcsh:Biology (General), lcsh:QD1-999, Immunology, pharmacogenetic, business, Pharmacogenetics
Abstract

Primary plasma cell leukemia (pPCL) is a rare and aggressive variant of multiple myeloma (MM) which may represent a valid model for high-risk MM. This disease is associated with a very poor prognosis, and unfortunately, it has not significantly improved during the last three decades. New high-throughput technologies have allowed a better understanding of the molecular basis of this disease and moved toward risk stratification, providing insights for targeted therapy studies. This knowledge, added to the pharmacogenetic profile of new and old agents in the analysis of efficacy and safety, could contribute to help clinical decisions move toward a precision medicine and a better clinical outcome for these patients. In this review, we describe the available literature concerning the genomic characterization and pharmacogenetics of plasma cell leukemia (PCL).

Published
2015

16. Clinical outcomes of 217 patients with acute erythroleukemia according to treatment type and line

Author

Antonio Almeida, Haifa Kathrin Al-Ali, Dietmar Geissler, Joan Bargay, Arjan A. van de Loosdrecht, Peter Krippl, Guillermo Deben, Sylvain Thepot, Raphael Itzykson, Ana Garrido, Richard Greil, Alois Lang, Eva Maria Autzinger, Jaime L. Wetzel, Lisa Pleyer, Pierre Fenaux, Reinhard Stauder, Ricardo Pinto, Peter Valent, Fernando Ramos, Mikkael A. Sekeres, Wolfgang R. Sperr, Jose F Falantes, Lionel Ades, María Díez-Campelo, Pellegrino Musto, Santiago Bonanad, Jamile M. Shammo, Thomas Prebet, Luca Maurillo, Maria Joao Costa, Sonja Burgstaller, Susana Esteves, Carmen Pedro, [Almeida, Antonio M.] IPOL, P-1200795 Lisbon, Portugal, [Esteves, Susana] IPOL, P-1200795 Lisbon, Portugal, [Prebet, Thomas] Inst Paoli Calmettes, Marseille, France, [Prebet, Thomas] Yale New Haven Med Ctr, New Haven, CT 06512 USA, [Itzykson, Raphael] Paris Diderot Univ, Hop St Louis, AP HP, F-75010 Paris, France, [Ades, Lionel] Paris Diderot Univ, Hop St Louis, AP HP, F-75010 Paris, France, [Fenaux, Pierre] Paris Diderot Univ, Hop St Louis, AP HP, F-75010 Paris, France, [Ramos, Fernando] Hosp Univ Leon, Leon 24071, Spain, [Al-Ali, Haifa] Univ Hosp Halle, D-06120 Halle, Germany, [Shammo, Jamile] Rush Univ, Med Ctr, Chicago, IN 60612 USA, [Pinto, Ricardo] Hosp Sao Joao, P-4200319 Oporto, Portugal, [Maurillo, Luca] Univ Tor Vergata, I-00173 Rome, Italy, [Wetzel, Jaime] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44195 USA, [Sekeres, Mikkael A.] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44195 USA, [Musto, Pellegrino] Referral Canc Ctr Basilicata, RCCS CROB, I-85028 Rionero In Vulture, Pz, Italy, [Van De Loosdrecht, Arjan A.] Vrije Univ Amsterdam, Med Ctr, Dept Hematol, NL-1081 HV Amsterdam, Netherlands, [Costa, Maria Joao] Hosp Santa Maria, Ctr Hosp Lisboa Norte, P-1649035 Lisbon, Portugal, [Burgstaller, Sonja] Hosp Wels Grieskirchen, Dept Internal Med 4, A-4600 Wels, Austria, [Stauder, Reinhard] Innsbruck Med Univ, Dept Internal Med Haematol & Oncol 5, A-6020 Innsbruck, Austria, [Autzinger, Eva M.] Wilhelminenspital Stadt Wien, Ctr Oncol & Hematol, Dept Internal Med 1, A-1160 Vienna, Austria, [Lang, Alois] Hosp Feldkirch, Internal Med, A-6800 Feldkirch, Austria, [Krippl, Peter] Hosp Furstenfeld, Dept Internal Med, A-8280 Furstenfeld, Austria, [Geissler, Dietmar] Klinikum Klagenfurt Worthersee, Dept Internal Med, A-9020 Portschach Am Worthersee, Austria, [Francisco Falantes, Jose] Hosp Univ Virgen Rocio, Seville 41013, Spain, [Pedro, Carmen] Hosp Mar, Barcelona 08003, Spain, [Bargay, Joan] Hosp Son Llatzer, Palma De Mallorca 07198, Spain, [Deben, Guillermo] Hosp Univ, La Coruna 15006, Spain, [Garrido, Ana] Hosp Santa Creu & Sant Pau, Barcelona 08026, Spain, [Bonanad, Santiago] Hosp Univ Ribera, Alzira 46600, Spain, [Diez-Campelo, Maria] Hosp Univ Salamanca, Salamanca 37007, Spain, [Thepot, Sylvain] CHU, F-49100 Angers, France, [Sperr, Wolfgang R.] Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, A-1090 Vienna, Austria, [Valent, Peter] Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, A-1090 Vienna, Austria, [Sperr, Wolfgang R.] Med Univ Vienna, Ludwig Boltzmann Cluster Oncol, A-1090 Vienna, Austria, [Valent, Peter] Med Univ Vienna, Ludwig Boltzmann Cluster Oncol, A-1090 Vienna, Austria, [Greil, Richard] Paracelsus Med Univ, Med Dept 3, A-5020 Salzburg, Austria, [Pleyer, Lisa] Paracelsus Med Univ, Med Dept 3, A-5020 Salzburg, Austria, [Greil, Richard] Salzburg Canc Res Inst, A-5020 Salzburg, Austria, [Pleyer, Lisa] Salzburg Canc Res Inst, A-5020 Salzburg, Austria, [Greil, Richard] Canc Cluster Salzburg, A-5020 Salzburg, Austria, [Pleyer, Lisa] Canc Cluster Salzburg, A-5020 Salzburg, Austria, [Greil, Richard] Arbeitsgemeinschaft Medikamentose Tumortherapie A, A-5020 Salzburg, Austria, [Pleyer, Lisa] Arbeitsgemeinschaft Medikamentose Tumortherapie A, A-5020 Salzburg, Austria, University of Salzburg, NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES, CCA - Cancer Treatment and quality of life, and Hematology

Subjects
Oncology, Male, modelos de riesgos proporcionales, humanos, Chronic myelomonocytic leukemia, 0302 clinical medicine, Bone Marrow, Antineoplastic Combined Chemotherapy Protocols, Conventional care regimens, Complete remission, Open-label, Spectroscopy, mediana edad, leucemia, Aged, 80 and over, anciano, Leukemia, análisis citogenético, resultado del tratamiento, protocolos de quimioterapia antineoplásica combinada, General Medicine, Middle Aged, adulto, análisis de supervivencia, 3. Good health, Computer Science Applications, Treatment Outcome, 030220 oncology & carcinogenesis, Cytogenetic Analysis, Acute erythroleukemia, Female, Median survival, acute erythroleukemia, azacitidine, decitabine, Adult, medicine.medical_specialty, Poor prognosis, azacitidina, Myelodysplastic syndromes, Catalysis, Article, Leucèmia -- Tractament, Inorganic Chemistry, 03 medical and health sciences, Acute myeloid-leukemia, Health-organization classification, Internal medicine, Cox proportional hazards regression, medicine, Overall survival, Older patients, Humans, In patient, Physical and Theoretical Chemistry, Molecular Biology, acute erythroleukemia, azacitidine, decitabine, Aged, Proportional Hazards Models, Retrospective Studies, business.industry, Stem-cell transplantation, Organic Chemistry, estudios retrospectivos, medicine.disease, Survival Analysis, Surgery, Acute erythroid leukemia, Leukemia, Erythroblastic, Acute, business, médula ósea, Biomarkers, 030215 immunology, Rare disease
Abstract

Acute erythroleukemia (AEL) is a rare disease typically associated with a poor prognosis. The median survival ranges between 3-9 months from initial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong survival in patients with myelodysplastic syndromes (MDS) and AML, but there is limited data of their efficacy in AEL. We collected data from 210 AEL patients treated at 28 international sites. Overall survival (OS) and PFS were estimated using the Kaplan-Meier method and the log-rank test was used for subgroup comparisons. Survival between treatment groups was compared using the Cox proportional hazards regression model. Eighty-eight patients were treated with HMAs, 44 front line, and 122 with intensive chemotherapy (ICT). ICT led to a higher overall response rate (complete or partial) compared to first-line HMA (72% vs. 46.2%, respectively; p, Publication costs were supported by the University of Salzburg.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results